Cariprazine
- Generic Name
- Cariprazine
- Brand Names
- Vraylar, Reagila
- Drug Type
- Small Molecule
- Chemical Formula
- C21H32Cl2N4O
- CAS Number
- 839712-12-8
- Unique Ingredient Identifier
- F6RJL8B278
- Background
Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT receptors and as an antagonist at serotonin 5-HT receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.
- Indication
Cariprazine is indicated for the treatment of schizophrenia in adults to manage both positive and negative symptoms. It is also indicated to monotherapy for acute management of manic or mixed episodes associated with bipolar I disorder (bipolar mania) in adults, and acute management of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.
- Associated Conditions
- Bipolar Disorder With Manic or Mixed Episodes, Depressive Episodes, Schizophrenia
Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 129
- Registration Number
- NCT01376076
- Locations
- 🇺🇸
Forest Investigative Site 003, Houston, Texas, United States
🇺🇸Forest Investigative Site 002, Willingboro, New Jersey, United States
🇺🇸Forest Investigative Site 004, Long Beach, California, United States
Safety and Efficacy of Cariprazine in Patients With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 617
- Registration Number
- NCT01104766
- Locations
- 🇺🇸
Synergy Clinical Research of Escondido, Escondido, California, United States
🇺🇸Excell Research, Inc, Oceanside, California, United States
🇺🇸Colorado Clinical Trials, Inc., Littleton, Colorado, United States
Long-term Study of Cariprazine in Patients With Schizophrenia
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 752
- Registration Number
- NCT01104792
- Locations
- 🇺🇸
Forest Investigative Site 044, Rockville, Maryland, United States
🇺🇸Forest Investigative Site 007, Flowood, Mississippi, United States
🇺🇸Forest Investigative Site 082, North Miami, Florida, United States
Safety and Efficacy of Cariprazine in Schizophrenia
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 446
- Registration Number
- NCT01104779
- Locations
- 🇮🇳
Forest Investigative Site 503, Ahmedabad, Gujarat, India
🇨🇴Forest Investigative Site 604, Pereira, Risaralda, Colombia
🇮🇳Forest Investigative Site 505, Vijayawada, Andhra Pradesh, India
Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 403
- Registration Number
- NCT01059539
- Locations
- 🇺🇸
Forest Investigative Site 015, Springdale, Arkansas, United States
🇺🇸Forest Investigative Site 004, Garden Grove, California, United States
🇺🇸Forest Investigative Site 010, Carson, California, United States
Safety and Efficacy of Cariprazine for Bipolar I Disorder
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 497
- Registration Number
- NCT01058668
- Locations
- 🇺🇸
Forest Investigative Site 025, St. Louis, Missouri, United States
🇷🇴Forest Investigative Site 206, Bucuresti, Romania
🇺🇦Forest Investigative Site 307, Kharkiv, Ukraine
Safety and Efficacy of Cariprazine for Mania
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 323
- Registration Number
- NCT01058096
- Locations
- 🇮🇳
Forest Investigative Site 112, Vizag, Andhra Pradesh, India
🇮🇳Forest Investigator Site 108, Varanasi, Durgakund, India
🇮🇳Forest Investigative Site 106, Vijayawada, Andhra Pradesh, India
Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 34
- Registration Number
- NCT00862992
- Locations
- 🇯🇵
Hoyu Hospital, Kure-City, Hiroshima-ken, Japan
Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: Antidepressant + placebo
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 231
- Registration Number
- NCT00854100
- Locations
- 🇺🇸
Forest Investigative Site 031, Memphis, Tennessee, United States
🇺🇸Forest Investigative Site 023, Memphis, Tennessee, United States
🇺🇸Forest Investigative Site 033, Atlanta, Georgia, United States
Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 234
- Registration Number
- NCT00852202
- Locations
- 🇺🇸
Forest Investigative Site 026, Orlando, Florida, United States
🇺🇸Forest Investigative Site 005, Encino, California, United States
🇺🇸Forest Investigative Site 006, Media, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.